26
|
Salati R, Marini G, Degiuli A, Dalprà L. Brown's syndrome associated with Smith-Magenis syndrome: Case report. Strabismus 2009; 4:139-43. [DOI: 10.3109/09273979609055049] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
27
|
Ferrari VD, Ferrari L, Grisanti S, Consoli F, Valcamonico F, Amoroso V, Rangoni G, Vassalli L, Marpicati P, Marini G. Needs in breast cancer patients (pts) during chemotherapy: Customer satisfaction evaluation. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e20679] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e20679 Background: Satisfied patients demonstrate higher levels of compliance for the course of their treatment and the probability of successful treatment completion thus considerably increases. Analysis of pts needs is the base of pts satisfaction. The present analysis aims to identify the needs of our in-outpatients who received chemotherapy. Methods: 134 pts with breast cancer who underwent chemotherapy during 3 months (from 15 September to 30 November) were eligible for study. We administered the “Need Evaluation Questionnaire” (NED) validated by U.O. Psiconcologia Istituto Nazionale Tumori Mi) to 125 pts after consent, 9 pts (7%) refused to answer items. NED was built on 23 items in 7 domains of necessity: 1) information on diagnoses, prognoses, diagnostics tests and treatments (items 1–4); 2) relationship between pts and physicians or nurses (items 5–8), 3) nursing and supportive care (items 9 -13) 4) Hospital service (item 14); 5) economical aspects (items 15–16); 6) psychological, ethical, spiritual care (items 17,18,19,23); 7) relationship with relative. NED makes a quantitative evaluation of necessity with simple questions. Eligibility criteria required age ≥ 18 yrs (median age of pts was 55 yrs), histologically proven breast cancer; at lest 1 completed cycles of neoadjuvant or adjuvant or palliative chemotherapy. 96 (77%) pts completed questionnaire by their self, and 29 pts (23%) were helped because of practical problems (infusional therapy, no glasses at so on ). We choose a descriptive quantitative statistical evaluation for every item. Results: 93 % of pts completed NED questionnaire. More significant data were reported afterward and answers were allocated among the 7 domains: 1) more information about prognosis was required by 52 % of pts; 2) 90 % of pts thought that physicians embroiled them in therapeutic choices, but 36% of pts required information about future and quality of life 3) 96% of pts considered very good nursing care; 4) positive for all pts 5) 26% of pts required more informations about insurance, tickets 6) 13 and 14 % of pts required psychological or spiritual relationship; 7) women generally had support by relatives. Conclusions: this analysis shows that needs of our pts generally received responses, but answers also emphasized assurances on pts’ future. No significant financial relationships to disclose.
Collapse
|
28
|
Grisanti S, Consoli F, Ferrari VD, Bercich L, Amoroso V, Rangoni G, Cetto GL, Dei Tos AP, Facchetti F, Marini G. Proliferation heterogeneity in synovial sarcoma (SS) defines different patterns of clinical outcome: A retrospective study of 32 patients. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e21511] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e21511 Background: SS is an aggressive soft tissue sarcoma (STS) characterized by a constitutive overexpression of the bcl-2 proteins and high proliferation rate (Ki67). The aim of the study was to evaluate prognostic value of proliferative activity and apoptosis in SS. Methods: A retrospective analysis of 32 patients treated at three oncology centers between January 2000 and August 2008 was conducted. Histologic diagnosis of SS was confirmed by FISH analysis of t(X;18). Bcl-2 and Ki67 were determined by immunohistochemistry at baseline and after neoadjuvant chemotherapy (CT). A cut-off value of 20% was established for Ki67. The bcl-2 gene status was evaluated by FISH in neoadjuvant subgroup. Treatment-induced pathological response (pCR) was defined as tumor necrosis of 100%. Endpoints were recurrence rate (RR), disease-free survival (DFS) and overall survival (OS). Clinical and pathological variables were considered in uni- and multivariate analysis. Results: 13/32 patients received an anthracycline/ifosfamide-based chemotherapy (CT) before surgery. 8 pts received concomitant radiotherapy. A median number of 3 cycles of neoadjuvant CT was administered. All patients underwent surgical resection and pathologic assessment of the coexpression of bcl-2 and Ki67 was evaluated in the resected specimens. At baseline, all samples showed immunoexpression of bcl-2 and 9/13 had Ki67 more than 20%. After neoadjuvant CT, Ki67 was downregulated <20% in 11/13 samples and bcl-2 was negative in 4/13 pts. At FISH analysis, bcl-2 gene was neither rearranged nor amplified. After a median follow-up of 21 months (range 13–64 months), 9/13 pts without pCR experienced progression disease and 5 of them were dead of SS. At uni- and multivariate analysis, both pCR and downregulation of bcl-2 and Ki67 activity had a significant impact on DFS and OS (p=0.03). Conclusions: 1. Downregulation of bcl-2 and Ki67 index after treatment could be a predictor of recurrence and overall survival. 2. SS is characterized by cellular heterogeneity in which a high proliferative compartment coexists with low proliferative/anti-apoptotic compartment with different response to treatment. No significant financial relationships to disclose.
Collapse
|
29
|
Vanturini M, Bighin C, Puglisi F, Contu A, Aitini E, Colucci G, Merlano MC, Paccagnella A, Marini G, Crinò L, Djazouli K, Barbato A. A multicenter phase II study of non-pegylated liposomal doxorubicin (MYOCET®) in combination with trastuzumab and docetaxel as first line therapy in metastatic breast cancer. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-3156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #3156
The objective of the phase II study is to evaluate the cardiotoxicity, general safety, and efficacy of non-pegylated liposomal doxorubicin, in combination with docetaxel and trastuzumab, as first line treatment of metastatic breast cancer.
 Patients and methods: Patients (n = 31) with metastatic HER2-overexpressing breast cancer, who had not previously received chemotherapy for metastatic disease, received non-pegylated liposomal doxorubicin (50 mg/m2), docetaxel (75 mg/m2) every 3 weeks and trastuzumab (2 mg/kg/week) for up to eight cycles, followed by trastuzumab alone for up to 52 weeks. Cardiotoxicity was defined as signs and/or symptoms of congestive heart failure (CHF) and/or an absolute decrease in left ventricular ejection fraction (LVEF) of ≥ 20 units or a decline to ≤ 45%. Patients were allowed to receive adjuvant doxorubicin or epirubicin to cumulative doses up to 240 mg/m2 or 450 mg/m2, respectively.
 Results: The mean LVEF at baseline was 62.8 ± 7.1% and decreased to 60.2 ± 6.5% at cycle 2, but did not change significantly during the rest of the study; mean values at cycle 8 and at the end of the study were 58.7 ± 7.0% and 57.3 ± 9.5% respectively. One case of symptomatic CHF occurred during the study.
 The most common adverse events were hematologic toxicities, alopecia, asthenia and fever. The Overall Response Rate was 65.5% (CR 31%, PR 34.5%).The median progression free survival was 15.5 months (95% CI 11-24 months). The average overall survival was 27.9 months.Conclusions: These results suggest that the combination of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab has shown a good cardiac safety profile at a long term follow up, comparatively to recent published results data in HET study. A promising efficacy including CR and PFS has been noted in 1st line MBC.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 3156.
Collapse
|
30
|
Villanacci V, Rossi E, Grisanti S, Bassotti G, Ferrari VD, Missale G, Minelli L, Cengia P, Marini G, Cestari R. Targeted therapy with trastuzumab in dysplasia and adenocarcinoma arising in Barrett's esophagus: a translational approach. MINERVA GASTROENTERO 2008; 54:347-353. [PMID: 19047975] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
AIM Human epidermal growth factor receptor (HER2) protooncogene, overexpressed/ amplified in preneoplastic lesions and in adenocarcinoma (ADC) of the esophagus, can be considered a target for treatment of esophageal dysplasia/ADC. The aim of this study was to evaluate the therapeutic role of the anti-HER2 monoclonal antibody, trastuzumab, in the management of ADC originating from HER2-positive Barrett's esophagus (BE). METHODS Two patients with high-grade dysplasia and ADC of the esophagus after esophageal mucosectomy and no metastatic disease were studied. Patients were not eligible for radical surgery or chemo-radiotherapy because of age and comorbidities. HER2 status was assessed by immunohistochemistry and fluorescence in situ hybridization. Additional immunohistochemical analyses were performed. The whole panel was analysed at baseline, after treatment and at follow-up. RESULTS At baseline, the two patients showed HER-2 overexpression/amplification in all areas of dysplasia and ADC but not in BE. Six months after treatment no significant differences in terms of endoscopical and histological patterns of the disease were found. HER-2, EGFR, TOPOII-alpha and anti-ssDNA analysis demonstrated a down-regulation of these markers and increased apoptosis. CONCLUSION This study demonstrates that this treatment is feasible. No clear evidence of dysplasia regression was observed. However, HER2 and TopoII-alpha downregulation and induction of apoptosis occurring 6 months after treatment encourages further investigation.
Collapse
|
31
|
Chekanov S, Derrick M, Magill S, Musgrave B, Nicholass D, Repond J, Yoshida R, Mattingly MCK, Antonioli P, Bari G, Bellagamba L, Boscherini D, Bruni A, Bruni G, Cindolo F, Corradi M, Iacobucci G, Margotti A, Nania R, Polini A, Antonelli S, Basile M, Bindi M, Cifarelli L, Contin A, De Pasquale S, Sartorelli G, Zichichi A, Bartsch D, Brock I, Hartmann H, Hilger E, Jakob HP, Jüngst M, Nuncio-Quiroz AE, Paul E, Samson U, Schönberg V, Shehzadi R, Wlasenko M, Brook NH, Heath GP, Morris JD, Capua M, Fazio S, Mastroberardino A, Schioppa M, Susinno G, Tassi E, Kim JY, Ibrahim ZA, Kamaluddin B, Wan Abdullah WAT, Ning Y, Ren Z, Sciulli F, Chwastowski J, Eskreys A, Figiel J, Galas A, Gil M, Olkiewicz K, Stopa P, Zawiejski L, Adamczyk L, Bołd T, Grabowska-Bołd I, Kisielewska D, Lukasik J, Przybycień M, Suszycki L, Kotański A, Słomiński W, Behrens U, Blohm C, Bonato A, Borras K, Ciesielski R, Coppola N, Fang S, Fourletova J, Geiser A, Göttlicher P, Grebenyuk J, Gregor I, Haas T, Hain W, Hüttmann A, Januschek F, Kahle B, Katkov II, Klein U, Kötz U, Kowalski H, Lobodzinska E, Löhr B, Mankel R, Melzer-Pellmann IA, Miglioranzi S, Montanari A, Namsoo T, Notz D, Parenti A, Rinaldi L, Roloff P, Rubinsky I, Santamarta R, Schneekloth U, Spiridonov A, Szuba D, Szuba J, Theedt T, Wolf G, Wrona K, Yagües Molina AG, Youngman C, Zeuner W, Drugakov V, Lohmann W, Schlenstedt S, Barbagli G, Gallo E, Pelfer PG, Bamberger A, Dobur D, Karstens F, Vlasov NN, Bussey PJ, Doyle AT, Dunne W, Forrest M, Rosin M, Saxon DH, Skillicorn IO, Gialas I, Papageorgiu K, Holm U, Klanner R, Lohrmann E, Schleper P, Schörner-Sadenius T, Sztuk J, Stadie H, Turcato M, Foudas C, Fry C, Long KR, Tapper AD, Matsumoto T, Nagano K, Tokushuku K, Yamada S, Yamazaki Y, Barakbaev AN, Boos EG, Pokrovskiy NS, Zhautykov BO, Aushev V, Borodin M, Kadenko I, Kozulia A, Libov V, Lisovyi M, Lontkovskyi D, Makarenko I, Sorokin I, Verbytskyi A, Volynets O, Son D, de Favereau J, Piotrzkowski K, Barreiro F, Glasman C, Jimenez M, Labarga L, Del Peso J, Ron E, Soares M, Terrón J, Zambrana M, Corriveau F, Liu C, Schwartz J, Walsh R, Zhou C, Tsurugai T, Antonov A, Dolgoshein BA, Gladkov D, Sosnovtsev V, Stifutkin A, Suchkov S, Dementiev RK, Ermolov PF, Gladilin LK, Golubkov YA, Khein LA, Korzhavina IA, Kuzmin VA, Levchenko BB, Lukina OY, Proskuryakov AS, Shcheglova LM, Zotkin DS, Abt I, Caldwell A, Kollar D, Reisert B, Schmidke WB, Grigorescu G, Keramidas A, Koffeman E, Kooijman P, Pellegrino A, Tiecke H, Vázquez M, Wiggers L, Brümmer N, Bylsma B, Durkin LS, Lee A, Ling TY, Allfrey PD, Bell MA, Cooper-Sarkar AM, Devenish RCE, Ferrando J, Foster B, Korcsak-Gorzo K, Oliver K, Robertson A, Uribe-Estrada C, Walczak R, Bertolin A, Dal Corso F, Dusini S, Longhin A, Stanco L, Bellan P, Brugnera R, Carlin R, Garfagnini A, Limentani S, Oh BY, Raval A, Ukleja J, Whitmore JJ, Iga Y, D'Agostini G, Marini G, Nigro A, Cole JE, Hart JC, Abramowicz H, Ingbir R, Kananov S, Levy A, Stern A, Kuze M, Maeda J, Hori R, Kagawa S, Okazaki N, Shimizu S, Tawara T, Hamatsu R, Kaji H, Kitamura S, Ota O, Ri YD, Costa M, Ferrero MI, Monaco V, Sacchi R, Solano A, Arneodo M, Ruspa M, Fourletov S, Martin JF, Stewart TP, Boutle SK, Butterworth JM, Gwenlan C, Jones TW, Loizides JH, Wing M, Brzozowska B, Ciborowski J, Grzelak G, Kulinski P, Luzniak P, Malka J, Nowak RJ, Pawlak JM, Tymieniecka T, Ukleja A, Zarnecki AF, Adamus M, Plucinski P, Eisenberg Y, Hochman D, Karshon U, Brownson E, Danielson T, Everett A, Kçira D, Reeder DD, Ryan P, Savin AA, Smith WH, Wolfe H, Bhadra S, Catterall CD, Cui Y, Hartner G, Menary S, Noor U, Standage J, Whyte J. Inclusive K(S);(0)K(S);(0) resonance production in ep collisions at HERA. PHYSICAL REVIEW LETTERS 2008; 101:112003. [PMID: 18851276 DOI: 10.1103/physrevlett.101.112003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/05/2008] [Indexed: 05/26/2023]
Abstract
Inclusive K_{S};{0}K_{S};{0} production in ep collisions at the DESY ep collider HERA was studied with the ZEUS detector using an integrated luminosity of 0.5 fb;{-1}. Enhancements in the mass spectrum were observed and are attributed to the production of f_{2}(1270)/a_{2};{0}(1320), f_{2};{'}(1525) and f_{0}(1710). Masses and widths were obtained using a fit which takes into account theoretical predictions based on SU(3) symmetry arguments, and are consistent with the Particle Data Group values. The f_{0}(1710) state, which has a mass consistent with a glueball candidate, was observed with a statistical significance of 5 standard deviations. However, if this state is the same as that seen in gammagamma-->K_{S};{0}K_{S};{0}, it is unlikely to be a pure glueball state.
Collapse
|
32
|
Ferrari VD, Grisanti S, Valcamonico F, Amoroso V, De Ponti S, Rangoni G, Marpicati P, Vassalli L, Simoncini E, Marini G. Bi-weekly fixed dose of gemcitabine (GEM) plus 24 hours infusion of cisplatin (CDDP) in advanced/metastastic pancreatic cancer (APC) patients: A phase II study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.15639] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
33
|
Guarneri P, Ferari VD, Grisanti S, Valcamonico F, Amoroso V, Rangoni G, Mapicati P, Vassalli L, Simoncini E, Marini G. Neurotoxicity in older colorectal patients with diabetes treated with oxaliplatin schedule: Our experience. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.20724] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
34
|
Marini G, Ceccarelli P, Mancia M. Characterization of the 7–12Hz EEG oscillations during immobile waking and REM sleep in behaving rats. Clin Neurophysiol 2008; 119:315-20. [DOI: 10.1016/j.clinph.2007.09.142] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2007] [Revised: 07/16/2007] [Accepted: 09/23/2007] [Indexed: 11/28/2022]
|
35
|
Ferrari VD, De Ponti S, Valcamonico F, Amoroso V, Grisanti S, Rangoni G, Marpicati P, Vassalli L, Simoncini E, Marini G. Deep electro-hyperthermia (EHY) with or without thermo-active agents in patients with advanced hepatic cell carcinoma: Phase II study. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.15168] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
15168 Background: Advanced HCC has no standard chemotherapy , all pts would be valuabled in clinical trials. We evaluated effectiveness and toxicity of capacitatively coupled low-frequency 13.56 MHz deep hyperthermia (Oncotherm-EHY 2000) treatment on chemo- refractory malignant primary liver cancer which underwent all other possible treatment. Methods: From February 2005 to July 2006, we enrolled 22 pts with advanced HCC. ECOG PS was 1 or O. Viral hepatic infection status was 7 HBV+, 8 HCV+, 1 HCV/HBV+. Median age was 67,5 y (range 63 -78), male/female 20/2 . 15 pts were uneligible for liver surgery, 3 pts received TACE, 1 PEI, 1 a lot of therapy. 7 pts were pre-treated with surgery, 2 also received TACE, 1 PEI and 1 a lot of therapy. 75% of pts were in stage C of BCLC classification. 2 pts had also distant metastases, 70% of pts had portal vein thromboses. 8 pts underwent only to EHY without CT. Schedule : EHY was achieved by arrangements of capacitative electrodes with a radiofrequency field of 13.56 Mhz (RF-DHT) at 80- 130 W equivalent to 41 °- 47° C for 60 minutes, 2 times/w for 5 weeks in combination with thermo-active agents . EHY was applied over 2 time a week over 1 hour as mono - combined therapy . Concomitant chemotherapy was oxaliplatin 50 mgr at fixed dose on D 1and D 15 . One cycle is 10 treatments of EHY ; 4 pts underwent 2 cycles and 2 pts to 3 cycles and 1 pt to 4 cycles . Median number of cycles was 1,5 (range 1–4), total EHY applications were 365. Results: EHY plus thermo-active drug is beneficial on clinical conditions off treated pts with an excellent compliance on out- patients. We observed 1 CR ( pt has only one bone metastases after 6 months without liver relapse), no PR, 25% of SD. Median survival time was 20’5 weeks (5 - 81+) We noted that 11 pts (50%) presented evidence of increasing well-being. Toxicity : 4 pts had skin reaction after application of EHY. In 3 pts we observed cutaneous hyperemia on the area of treatment and mild burn on the skin ; all symptoms disappeared after local steroid therapy , treatment was interrupted until resolution . Conclusions: Low toxicity and clinical benefit will be confirmed in further clinical studies. Capacitively coupled low-frequency 13.56 deep-hyperthermia is feasible for chemo-refractory HCC. No significant financial relationships to disclose.
Collapse
|
36
|
Marini G, Grisanti S, Ruggeri G, Ardighieri L, Simoncini E, Amoroso V, Rangoni G, Valcamonico F, Lucini L, Facchetti F. CXCR4/SDF-1 expression in early breast cancer (BC) is not influenced by circulating estrogens serum levels. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.21159] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
21159 Background: The chemokine SDF-1 and its receptor CXCR4 have been found to enhance the metastatic potential of BC cells and correlate with a poorer prognosis of BC patients. Estradiol is a known mitogenic factor for BC cells. SDF-1 has been reported to be an estradiol (E2)-inducible autocrine growth factor that supports the growth of breast cancer cell lines in vitro. The aim of this study was to verify whether estrogens serum levels may influence SDF-1 and CXCR4 expression in vivo, in a series of patients with early stage BC. Methods: 68 patients sequentially observed at the Spedali Civili di Brescia from 2001 to 2002, with a diagnosis of T1a,b,c, N0 breast cancer were retrospectively analysed. CXCR4 and SDF-1 expression was determined by immunohistochemistry with anti-human CXCR4 (Clone 44716) and anti-human SDF-1 (Clone 79018) monoclonal antibodies (R&D Systems, Minneapolis, USA) followed by incubation with the EnVision peroxidase kit (Dakocytomation, Glostrup, Denmark). A serum sample was obtained from all patients at baseline before surgery. Serum estrone (E1) and estradiol (E2) were measured by radioimmunoassay by using commercial kits (Alifax, Padua, IT and Ortho-Clinical Diagnostics, Amersham, UK, respectively). Results: Estrogens serum levels analysis revealed elevated levels of E1 in 9/54 (16%) post-menopausal patients, while E2 levels were in the normal ranges. SDF-1 was expressed in 68/68 (100%) patients with a diffuse and intense cytoplasmatic pattern of staining and CXCR4 was coexpressed in 15/68 (22%) patients with a predominant faint nuclear distibution (p 0,06). No significant correlations were found between CXCR4, SDF-1 and E1 or E2, respectively, as well as with other clinico-pathological characteristics. After a median follow-up of 48 months, 3/68 (4%) patients which all resulted CXC4/SDF1-positive, relapsed and are dead for metastatic disease. Conclusions: This study demonstrates that in T1N0 BC patients: 1) SDF-1 is high levels in the majority of cases; 2) CXCR4 is expressed in approximately 20% of cases with restriction to the nucleus and 3) serum levels of circulating E2 and E1 in pre- or post-menopausal patients, respectively, do not influence CXCR4/SDF-1 expression on breast cancer cells. No significant financial relationships to disclose.
Collapse
|
37
|
Grisanti S, Facchetti F, Dei Tos AP, Rossi E, Ardighieri L, Ferrari VD, Amoroso V, Bercich L, Ippolito V, Marini G. Loss of CXCR4 nuclear immunoreactivity in synovial sarcoma (SS) correlates with poor survival. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.10069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10069 Background: The chemokine receptor CXCR4 has been found to be expressed in mesenchymal neoplasms including osteosarcoma, rhabdomyosarcoma, Ewing's sarcoma and SS. Gene products of the HER oncogenic family, such as EGFR and HER2, have been described to be overexpressed in SS and we previously demonstrated coexpression of CXCR4 and EGFR but not HER2 in SS patients. In this study we analysed CXCR4 expression in terms of subcellular localization and extended results to 15 SS patients. Methods: Fifteen SS patients were included in the study. In all cases morphological diagnoses were confirmed molecularly by FISH or RT-PCR specific for t(X;18). HER2 and EGFR expression were determined by immunohistochemistry (IHC) while HER2 gene status was assessed by FISH analysis. CXCR4 expression was determined with an anti-human CXCR4 monoclonal antibody (Clone 44716, R&D Systems, Minneapolis, USA) followed by incubation with the EnVision peroxidase kit (Dakocytomation, Glostrup, Denmark). CXCR4 nuclear vs cytoplasmic expression was correlated with outcome. Results: In all samples IHC analysis for HER2 was negative and no amplification was found by FISH. EGFR expression was observed in 13/15 patients. CXCR4 immunoreactivity was identified in 9/15 cases. CXCR4 and EGFR were coexpressed in 8/15 tumors. Follow-up ranged from 9 to 127 months. After a median follow-up of 39 months, 7 patients were dead of SS, 8 patients were alive (7 of them are disease-free and one has evident disease in the retroperitoneum). All alive and disease-free patients showed nuclear CXCR4 expression whereas 6/7 dead patients expressed cytoplasmic or membrane CXCR4 (p = 0.0008). Conclusions: Loss of nuclear CXCR4 expression is associated with fatal course and may represent a novel prognostic factor. CXCR4 is frequently coexpressed with EGFR but not with HER2. In contrast with previous reports HER2 seems not involved in the carcinogenesis of SS. No significant financial relationships to disclose.
Collapse
|
38
|
Chekanov S, Derrick M, Krakauer D, Loizides JH, Magill S, Miglioranzi S, Musgrave B, Repond J, Yoshida R, Mattingly MCK, Antonioli P, Bari G, Basile M, Bellagamba L, Boscherini D, Bruni A, Bruni G, Cara Romeo G, Cifarelli L, Cindolo F, Contin A, Corradi M, De Pasquale S, Giusti P, Iacobucci G, Margiotti A, Montanari A, Nania R, Palmonari F, Pesci A, Sartorelli G, Zichichi A, Aghuzumtsyan G, Bartsch D, Brock I, Goers S, Hartmann H, Hilger E, Irrgang P, Jakob HP, Kind O, Meyer U, Paul E, Rautenberg J, Renner R, Stifutkin A, Tandler J, Voss KC, Wang M, Weber A, Bailey DS, Brook NH, Cole JE, Heath GP, Namsoo T, Robins S, Wing M, Capua M, Mastroberardino A, Schioppa M, Susinno G, Kim JY, Kim YK, Lee JH, Lim IT, Pac MY, Caldwell A, Helbich M, Liu X, Mellado B, Ning Y, Paganis S, Ren Z, Schmidke WB, Sciulli F, Chwastowski J, Eskreys A, Figiel J, Galas A, Olkiewicz K, Stopa P, Zawiejski L, Adamczyk L, Bołd T, Grabowska-Bołd I, Kisielewska D, Kowal AM, Kowal M, Kowalski T, Przybycień M, Suszycki L, Szuba D, Szuba J, Kotański A, Słomiński W, Adler V, Behrens U, Bloch I, Borras K, Chiochia V, Dannheim D, Drews G, Fourletova J, Fricke U, Geiser A, Göttlicher P, Gutsche O, Haas T, Hain W, Hillert S, Kahle B, Kötz U, Kowalski H, Kramberger G, Labes H, Lelas D, Lim H, Löhr B, Mankel R, Melzer-Pellmann IA, Nguyen CN, Notz D, Nucio-Quiroz AE, Polini A, Raval A, Rurua L, Schneekloth U, Stösslein U, Wolf G, Youngman C, Zeuner W, Schlenstedt S, Barbagli G, Gallo E, Genta C, Pelfer PG, Bamberger A, Benen A, Karstens F, Dobur D, Vlasov NN, Bell M, Bussey PJ, Doyle AT, Ferrando J, Hamilton J, Hanlon S, Saxon DH, Skillicorn IO, Gialas I, Carli T, Gosau T, Holm U, Krumnack N, Lohrmann E, Milite M, Salehi H, Schleper P, Stonjek S, Wichmann K, Wick K, Ziegler A, Ziegler A, Collins-Tooth C, Foudas C, Gonçalo R, Long KR, Tapper AD, Cloth P, Filges D, Kataoka M, Nagano K, Tokushuku K, Yamada S, Yamazaki Y, Barakbaev AN, Boos EG, Pokrovskiy NS, Zhautykov BO, Son D, Piotrzkowski K, Barreiro F, Glasman C, González O, Labarga L, del Peso J, Tassi E, Terrón J, Vázquez M, Zambrana M, Barbi M, Corriveau F, Gliga S, Lainesse J, Padhi S, Stairs DG, Walsh R, Tsurugai T, Antonov A, Danilov P, Dolgoshein BA, Gladkov D, Sosnovtsev V, Suchkov S, Dementiev RK, Ermolov PF, Golubkov YA, Katkov II, Khein LA, Korzhavina IA, Kuzmin VA, Levchenko BB, Lukina OY, Proskuryakov AS, Shcheglova LM, Zotkin SA, Coppola N, Grijpink S, Koffeman E, Kooijman P, Maddox E, Pellegrino A, Schagen S, Tiecke H, Velthuis JJ, Wiggers L, de Wolf E, Brümmer N, Bylsma B, Durkin LS, Ling TY, Cooper-Sarkar AM, Cottrell A, Devenish RCE, Foster B, Grzelak G, Gwenlan C, Patel S, Straub PB, Walczak R, Bertolin A, Brugnera R, Carlin R, Dal Corso F, Dusini S, Garfagnini A, Limentani S, Longhin A, Parenti A, Posocco M, Stanco L, Turcato M, Heaphy EA, Metlica F, Oh BY, Whitmore JJ, Iga Y, D’Agostini G, Marini G, Nigro A, Cormack C, Hart JC, McCubbin NA, Heusch C, Park IH, Pavel N, Abramowicz H, Gabareen A, Kananov S, Kreisel A, Levy A, Kuze M, Fusayasu T, Kagawa S, Kohno T, Tawara T, Yamashita T, Hamatsu R, Hirose T, Inuzuka M, Kaji H, Kitamura S, Matsuzawa K, Ferrero MI, Monaco V, Sacchi R, Solano A, Arneodo M, Ruspa M, Koop T, Martin JF, Mirea A, Butterworth JM, Hall-Wilton R, Jones TW, Lightwood MS, Sutton MR, Targett-Adams C, Ciborowski J, Ciesielski R, Łużniak P, Nowak RJ, Pawlak JM, Sztuk J, Tymieniecka T, Ukleja A, Ukleja J, Żarnecki AF, Adamus M, Plucinski P, Eisenberg Y, Gladilin LK, Hochman D, Karshon U, Riveline M, Kçira D, Lammers S, Li L, Reeder DD, Rosin M, Savin AA, Smith WH, Deshpande A, Dhawan S, Bhadra S, Catterall CD, Fourletov S, Hartner G, Menary S, Soares M, Standage J. Erratum: Bottom photoproduction measured using decays into muons in dijet events inepcollisions ats=318 GeV[Phys. Rev. D70, 012008 (2004)]. Int J Clin Exp Med 2006. [DOI: 10.1103/physrevd.74.059906] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
39
|
Grisanti S, Rossi E, Ardighieri L, Farisoglio C, Ferrari VD, Bercich L, Simoncini E, Marini G, Facchetti F. CXCR4, EGFR and HER2 expression in patients with high-risk synovial sarcoma (SS): A clinicopathologic study. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.9580] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9580 Background: CXCR4 is overexpressed in many human tumors and plays important role in targeted metastasis. CXCR4 activation has been described in osteosarcoma, rhabdomyosarcoma and Ewing’s sarcoma both in vivo and in vitro, but its role has not been elucidated in SS yet. EGFR and Her2/neu, have been described to be overexpressed in patients with SS and proposed as potential therapeutic targets. Because CXCR4 and Her2 have been found to be functionally linked in breast cancer cell lines, we characterized SS in terms of CXCR4, Her2 and EGFR coexpression. Materials and Methods: Six patients sequentially observed at the Spedali Civili di Brescia from 1999 to 2005, with a diagnosis of synovial sarcoma were included in the study. The diagnosis of SS, a FISH analysis for t(X;18) was performed by using a commercial probe specific for the SYT gene breakpoint region (18q11) or by RT-PCR. Her2 and EGFR expression were determined by IHC and Her2 gene amplification by FISH analysis. CXCR4 expression was determined by IHC with anti-human CXCR4 monoclonal antibody (Clone 44716, R&D Systems) followed by incubation with the EnVision peroxidase kit (Dakocytomation, Glostrup, Denmark). Results: All patients were classified high-risk (stage III-IV) according to the AJCC/UICC VI Edition Staging System for soft tissue sarcomas. In all samples IHC analysis for Her2 was negative and no amplification was found by FISH. EGFR staining demonstrated positivity in 5 patients out of 6. CXCR4 reactivity was identified in 4 cases (nuclear staining in 3 and membrane staining in 1). CXCR4 and EGFR were coexpressed in 3 tumors. After a median follow-up of 24 months, 2 patients are dead of SS, 4 patients are alive, 3 of them are disease-free and one relapsed to the lung. The 3 patients alive and disease-free resulted positive for nuclear CXCR4 and EGFR while membrane CXCR4 was expressed in one dead patient. Conclusion: This study provides evidence that CXCR4 is expressed in cases of SS and is frequently coexpressed with EGFR but not with Her2. Due to the small size of this series it is not possible to establish any definitive prognostic or predictive value of CXCR4. However, nuclear expression of CXCR4 seems to be associated with a more indolent behaviour of the tumor and requires confirmation in larger series. No significant financial relationships to disclose.
Collapse
|
40
|
Buttolo L, Giunta F, Ferrari VD, Grisanti S, Marini G, Mortini P. Alternative schedules of adjuvant temozolomide in glioblastoma multiforme: A 6-year experience. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.1511] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1511 Background: Temozolomide (TMZ) is an oral alkylating agent with proven efficacy in the therapy of glioblastoma multiforme (GBM). The activity of TMZ is drug-exposure dependent, however dosages are primarily limited by myelotoxicity. In the attempt to increase survival while limiting toxicity, we treated GBM patients (pts) with one of 3 alternative adjuvant TMZ schedules, including a low-dose daily regimen. Methods: We assessedthe overall survival and the development of grade 3–4 myelotoxicity in pts with GBM who were treated in our centre (November 1998-October 2005), following surgery, with one of the following TMZ schedules: standard schedule (SS: 200–300 mg/m2 × 5 days, every 28 days); extended schedule (ES: 150 mg/m2 × 7 days every 15 days); daily schedule (DS: 75 mg/m2 daily). Pts were treated until death or tumour progression. The analysis of survival was based on the Kaplan-Meier (KM) and the Cox models. Adverse events were graded according to NCICTC 3.0. Results: We evaluated 117 pts (73 m, 44 f, avg. age 57 yrs, 53% received radiotherapy, RT) with histologically diagnosed gliomas (GBM=92.3%) treated with TMZ SS (tot pts=48, RT pts=22, no. cycles: 1÷33, avg 6) or ES (tot pts=35; RT pts=19, no. cycles: 1÷43, avg 16) or DS (tot pts=34; RT pts=21, days of treatment: 25÷671, avg 212). The overall survival significantly differed among the 3 schedules (KM), with DS providing the best outcome (p=0.0357, log-rank). Median survival time was markedly increased in DS pts (DS=29.47 months; ES=15.73 months; SS=11.90 months) as well as the survival rate at 2 yrs after diagnosis (DS=51%; ES=30%; SS=21%). DS, but not ES, significantly reduced the mortality hazard ratio (HR) compared to SS (Cox: HR=0.494; IC95% 0.253–0.966, p=0.039). Grade 3–4 myelotoxicity (leukopenia, LP; neutropenia, NP; thrombocytopenia,TP) occurred less frequently with DS (NP=2.9%; TP=2.9%; any=5.9%) than with ES (LP=11.4%; NP=14.3%; TP=17.1%; any=28.6%) and SS (LP=14.6%; NP=8.3%; TP=20.8%; any=22.9%). Conclusions: In our experience with adjuvant TMZ in GBM, a continuous daily dose of 75 mg/m2 was on the whole more advantageous than a standard monthly or a biweekly regimen, as it resulted in the highest overall survival with the lowest hematologic toxicity. No significant financial relationships to disclose.
Collapse
|
41
|
Marini G, Calvani M, Ceccarelli P, Mancia M. Behavioral and electrophysiological changes induced by acetyl-L-carnitine in aged freely-moving rats. Arch Ital Biol 2006; 144:33-43. [PMID: 16425616] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
In chronically-implanted, drug-free, behaving aged Fischer rats, intracerebroventricularly (i.c.v.) and intraperitoneally (i.p.) acetyl-L-carnitine (ALCAR) injections powerfully enhanced motor behavior and head movements aimed at attention and exploratory activity. This effect was dose-dependent and associated with the abolition or substantial reduction of the incidence and duration of the spontaneous EEG generalized hypersynchronous patterns termed High Voltage Spindle (HVS), with an increase in EEG monitored theta activity. The results suggest that ALCAR may stimulate the motivational system and disrupt the hypersynchronous processes by inhibiting the GABAergic thalamic reticular neurons and/or activating the brain stem cholinergic reticular system (pedunculo pontine tegmental, PPT and laterodorsal tegmental, LDT nuclei).
Collapse
|
42
|
Ferrari VD, Valcamonico F, Amoroso V, Vassalli L, Grisanti S, Marpicati P, Simoncini E, Rangoni G, Marini G. FAFOXIRI: A phase II trial of an alternating regimen of irinotecan/5-fluoruracil/folinic acid and oxaliplatin/5-fluoruracil/folinic acid in metastatic colorectal cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3660] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
43
|
Simoncini E, Ferrari VD, Amoroso V, Valcamonico F, Grisanti S, Vassalli L, Marpicati P, Montini E, Rangoni G, Marini G. Bi-weekly administration of pegylated liposomal doxorubicin plus paclitaxel in metastatic breast cancer (MBC) patients: A phase II study. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.844] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
44
|
Ferrari VD, Tassi GF, Marchetti P, Trignani M, Valcamonico F, Marini G. Intracavitary IL-2 immunotherapy in malignant pleural effusion. Phase II study. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
45
|
Simoncini E, Valcamonico F, Amoroso V, Manganoni AM, Ferrari VD, Vassalli L, Rangoni G, Grisanti S, Marpicati P, Marini G. Safety and toxicity profile of high-dose IFN-α2b in 44 patients with malignant melanoma. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7570] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
46
|
Marini G, Simoncini E, Valcamonico F, Amoroso V, Vassalli L, Rangoni G, Grisanti S, Marpicati P, Tiberio GAM, Ferrari VD. Gemcitabine (Gem) plus celecoxib in advanced pancreatic carcinoma: a phase II study. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.4103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
47
|
Baumgartner C, Böhm C, Baumgartner D, Marini G, Weinberger K, Olgemöller B, Liebl B, Roscher AA. Supervised machine learning techniques for the classification of metabolic disorders in newborns. Bioinformatics 2004; 20:2985-96. [PMID: 15180934 DOI: 10.1093/bioinformatics/bth343] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
MOTIVATION During the Bavarian newborn screening programme all newborns have been tested for about 20 inherited metabolic disorders. Owing to the amount and complexity of the generated experimental data, machine learning techniques provide a promising approach to investigate novel patterns in high-dimensional metabolic data which form the source for constructing classification rules with high discriminatory power. RESULTS Six machine learning techniques have been investigated for their classification accuracy focusing on two metabolic disorders, phenylketo nuria (PKU) and medium-chain acyl-CoA dehydrogenase deficiency (MCADD). Logistic regression analysis led to superior classification rules (sensitivity >96.8%, specificity >99.98%) compared to all investigated algorithms. Including novel constellations of metabolites into the models, the positive predictive value could be strongly increased (PKU 71.9% versus 16.2%, MCADD 88.4% versus 54.6% compared to the established diagnostic markers). Our results clearly prove that the mined data confirm the known and indicate some novel metabolic patterns which may contribute to a better understanding of newborn metabolism.
Collapse
|
48
|
Marini G, Ceccarelli P, Mancia M. Spontaneous K-complexes in behaving rats. Arch Ital Biol 2004; 142:59-67. [PMID: 15143624] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]
Abstract
The K-complex (KC) is an electrographic rhythmic pattern present in human and cat sleep EEG. In long-term multisite videoEEG recordings in behaving Sprague-Dawley (SD) rats, well-defined spontaneous KCs were observed during sleep. Sprague-Dawley rats were implanted with multiple electrodes bilaterally along the antero-posterior axes at the locations F1, F2, F7, F8, T3, T4, P3, P4, all against a ground reference placed in the midline above the cerebellum. Multiple, closely spaced cortical electrodes allowed two-dimensional surface brain mapping of the power spectra distribution. Two silver wires were also inserted into nuchal muscles to record EMG activity. Each rat was monopolarly recorded from 0900 h to 1500 h in a natural dark-light rodents, we examined the patterns of appearance in various conditions, the progression through a full sleep-waking cycle, the shape, density, spectral components, and spatial distribution in power spectra. The rat KC appears to share similar features with the human and cat KC.
Collapse
|
49
|
Ferrari V, Vassalli L, Rangoni G, Grisanti S, Simoncini E, Amoroso V, Marpicati P, Valcamonico F, Maissouradze A, Marini G. 245 Three drugs schedulein metastatic colorectal cancer (MCC). A phase II study of sequential Irinotecan (CPT11), oxaliplatin (I-OHP) plus folinic acid (FA) and short fluorouracil (5FU) infusion. EJC Suppl 2003. [DOI: 10.1016/s1359-6349(03)90278-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
50
|
Corrao CR, Luzi A, Marini G. [Accidents among ambulance employees: epidemiologic features]. GIORNALE ITALIANO DI MEDICINA DEL LAVORO ED ERGONOMIA 2003; 25 Suppl:196-7. [PMID: 14979147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]
Abstract
The accidents have been esteemed that are verified in four years in a group of 824 employees. The study has underlined a meaningful percentage (30.1%) of road accidents. This suggests the opportunity of contemplate preventive actions: corrected maintenance of the ambulance, control of the conditions of environmental comfort, organization of the job, individualization of conditions that reduces the attention and the concentration, as the use of alcohol and of other substances.
Collapse
|